2-Polysubstituted Aromatic Ring-Pyrimidine Derivatives for Chk1 Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments, particularly chemotherapy, face challenges due to poor selectivity and the development of drug resistance, necessitating the need for more targeted and less toxic therapies that can effectively inhibit tumor cell growth without harming normal cells.
Innovation Solution
Development of 2-polysubstituted aromatic ring-pyrimidine derivatives with Chk1 inhibition capabilities, which are designed to selectively target and inhibit the Chk1 protein in tumor cells, enhancing the sensitivity of tumor cells to chemotherapy and radiation therapy while minimizing side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional chemotherapeutic drugs are used to treat malignant tumors, then tumor cell growth is inhibited, but toxic side effects and drug resistance occur due to poor selectivity
Solution Approach 1:
The patent applies local quality by designing the pyrimidine derivative with specific substituent patterns (R1-R6 groups at defined positions) that create localized interactions with the Chk1 kinase binding site. This targeted molecular architecture enables selective inhibition of Chk1 in tumor cells while sparing normal cells, thereby maintaining anticancer activity while reducing toxic side effects associated with non-selective chemotherapy
2Reliability
If traditional chemotherapeutic drugs are used to treat malignant tumors, then tumor cell growth is inhibited, but drug resistance develops during treatment
Solution Approach 1:
The patent employs preliminary action by developing Chk1 inhibitors that preemptively disrupt the DNA damage response pathway before tumor cells can develop resistance mechanisms. By selectively inhibiting Chk1 kinase activity, the compound prevents the adaptive survival responses that lead to drug resistance, thereby maintaining long-term treatment effectiveness
Solution Approach 2:
The patent applies parameter changes by modifying the molecular structure of the pyrimidine core with various substituent combinations (R1-R6 groups) to optimize Chk1 binding affinity and selectivity. These structural parameter adjustments enhance the drug's ability to inhibit Chk1 while minimizing off-target effects that contribute to resistance development
3Measurement precision
If single-targeted drugs are used for cancer treatment, then specific molecular targets are inhibited, but treatment is insufficient due to tumor complexity and genetic diversity
Solution Approach 1:
The patent applies universality by designing the pyrimidine derivative to perform multiple functions: it selectively inhibits Chk1 kinase while also sensitizing tumor cells to DNA-damaging agents and radiation therapy. This multi-functional approach addresses the complexity of tumor biology by simultaneously targeting the DNA damage response pathway and enhancing the efficacy of conventional treatments, thereby improving overall therapeutic effect despite the single-molecule design
Data Source
AI summary
The present invention provides a 2-polysubstituted aromatic ring-pyrimidine derivative and an optical isomer thereof, or a pharmaceutically acceptable salt or solvate thereof, the compound, and an optical isomer thereof or a pharmaceutically thereof acceptable salts or solvates can be used in the preparation of anti-tumor drugs. The invention designs and synthesizes a series of novel small molecule Chk1 inhibitors by using N-substituted pyridin-2-aminopyrimidine obtained by structure-based virtual screening as a lead compound, and carries out Chk1 kinase inhibitory activity test. The experiment confirmed that said compounds possess potent anticancer activity, Chk1 kinase inhibitory activity, and are promising Chk1 inhibitors, and can be used as new cancer therapeutic drugs, which can be applied to treat solid tumors or hematologic tumors related to proliferative disease of human or animal. The 2-polysubstituted aromatic ring-pyrimidine derivatives provided by the present invention has the structure of the formula I: